Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P514. Efficacy of dose intensification of anti-TNF therapy in Crohn's disease – single center experience
Authors:

Z. Szepes1, K. Farkas1, M. Szücs2, F. Nagy1, A. Bálint1, T. Wittmann1, T. Molnár1, 1University of Szeged, First Department of Medicine, Szeged, Hungary, 2University of Szeged, Department of Medical Physics and Informatics, Szeged, Hungary

P514

Need for anti-TNF escalation in Inflammatory Bowel Disease - A single center experience

Authors:

S. Fernandes*, C. Moura, P. Santos, P. Sousa, L. Correia, P. Moura Santos, A. Valente, A. Rita Gonçalves, C. Baldaia, N. Fatela, F. Serejo, J. Velosa

Centro Hospitalar Lisboa Norte, Gastrenterology, Lisbon, Portugal

P515.

Disease-related knowledge in inflammatory bowel disease

Authors:

M. Eusébio, P. Caldeira, A.L. Sousa, A. Gião Antunes, A.M. Vaz, H. Guerreiro, Centro Hospitalar do Algarve, Gastroenterology, Faro, Portugal

P515. Efficacy of anti-TNF alpha therapy in patients receiving tuberculosis chemoprophylaxis
Authors:

I. Gîrleanu1, A.-M. Singeap1, C. Cojocariu1, O. Stoica1, C. Sfarti1, A. Trifan1, 1University of Medicine and Pharmacy Gr. T. Popa, Gastroenterology, Iasi, Romania

P515

Basic laboratory parameters of inflammation compared to serum hepcidin level in inflammatory bowel disease (IBD)

Authors:

R. Dudkowiak*, K. Neubauer, E. Poniewierka

Wroclaw Medical University, Department of Gastroenterology and Hepatology, Wroclaw, Poland

P516.

Discrepancy between fecal biomarkers and their intestinal gene expression in ulcerative colitis: Results from an anti-IL-13 antibody study

Authors:

W. Reinisch1, J. Panes2, K. Page3, S. Khurana4, F. Hua3, G.M. Comer3, M. Hinz3, T. McDonnell Moorehead3, F. Cataldi3, 1Medical University of Vienna, Internal Medicine/Gastroenterology, Vienna, Austria, 2Hospital Clinic I Provincial, Department of Inflammatory Disease, Barcelona, Spain, 3Pfizer Inc., Gastroenterology, Cambridge, United States, 4Premier Medical Group, Gastroenterology, Poughkeepsie, New York, United States

P516. Efficacy of adalimumab in refractory ulcerative colitis in clinical practice
Authors:

M. Lequoy1, P. Seksik2, Y. Bouhnik3, M. Allez4, F. Carbonnel5, A. Bourrier1, H. Sokol2, L. Beaugerie2, J. Cosnes2, 1Hôpital Saint Antoine, 75012, Paris, France, 2Hôpital Saint Antoine, Gastro-Entérologie, Paris, France, 3Hôpital Beaujon, 92, Clichy, France, 4Hôpital Saint Louis, 75010, Paris, France, 5CHU de Bicêtre, 94, Le Kremlin-Bicêtre, France

P516

Immunisation status and factors influencing vaccination decision-making in patients with inflammatory bowel disease

Authors:

E. Waszczuk1, K. Waszczuk*2, A. Mulak1, L. Szenborn2, L. Paradowski1

1Wroclaw Medical University, Department of Gastroenterology and Hepatology, Wroclaw, Poland, 2Wroclaw Medical University, Department of Pediatrics and Infectious Diseases, Wroclaw, Poland

P517.

Discrepancy between efficiency and effectiveness of biological therapy in inflammatory bowel disease: EFIFECT study

Authors:

D. Ginard1, S. Khorrami1, L. Pérez-Carazo1, E. Tavío2, A. López-Sanromán2, M. García-Alvaredo3, F. Muñoz3, L. Ibañez4, I. Marín-Jiménez4, J. Guevara5, F. Casellas5, 1Hospital Universitario Son Espases, Gastroenterology, Palma de Mallorca, Spain, 2Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain, 3Complejo Hospitalario de León, Gastroenterology Unit, León, Spain, 4Hospital Universitario Gregorio Marañón, Gastroenterology, Madrid, Spain, 5Hospital Universitari Vall d'Hebron, Unitat Atenció Crohn-Colitis, Barcelona, Spain

P517. Evaluating Adalimumab drug and antibody levels as predictors of clinical and laboratory response in Crohn's disease patients
Authors:

Y. Mazor1, U. Koplov2, D. Ben Hur1, R. Almog1, M. Waterman1, S. Ben-Horin2, Y. Chowers1, 1Rambam Health Care Campus, Department of Gastroenterololgy, Israel, 2Chaim Sheba Medical Center, Tel Hashomer, Gastroenterology, Tel Aviv, Israel

P517

Efficacy of antisecretory factor in reducing high intestinal output in patients with ileostomy for Crohn's disease

Authors:

M.L. Scribano*, R. Monterubbianesi, A. Kohn

AO San Camillo Forlianini, Gastroenterology Operative Unit, Rome, Italy

P518.

Discordance among patients and parents regarding the perceived source of symptom relapse in young inflammatory bowel disease patients

Authors:

K.O. Kim1, B.I. Jang1, C.H. Yang2, S.B. Kim1, 1Yeungnam University College of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Daegu, Korea, Republic of, 2Dongguk University College of Medicine, Division of gastroenterology and Hepatology, department of Internal Medicine, Kyungju, Korea, Republic of

P518. Does thromboprophylaxis in ulcerative colitis work? Data from the UK IBD audit
Authors:

R. Lynch1, A. Protheroe2, M. Roughton2, I. Arnott1, UK IBD Audit Steering Group2, 1NHS Lothian, Gastroenterology, Edinburgh, United Kingdom, 2RCP, CEEU, London, United Kingdom

P518

Five year outcomes of Crohn's small bowel strictures treated with double balloon enteroscopic dilatation.

Authors:

N.S. Ding*, S. Mohammad, P. Hendy, A. Humphries, A. Hart

St Mark's Hospital, Inflammatory Bowel Disease Unit, London, United Kingdom

P519.

Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocecal resection for Crohn's disease: results from the MULTIPER database

Authors:

P.G. Kotze1, Y. Suzuki2, T. Yamamoto3, S. Danese4, R. Saad-Hossne5, F. Teixeira6, I. Albuquerque7, R. Silva1, I. Barcelos1, A. Yamada2, L. Kotze8, M. Sacchi9, M. Olandoski10, A. Spinelli9,11, 1Cajuru University Hospital – Catholic University of Parana, Colorectal Surgery Unit, Curitiba, Brazil, 2Toho University – Sakura Medical Center, Internal Medicine, Chiba, Japan, 3Yokkaichi Social Insurance Hospital, IBD Unit, Yokkaichi, Japan, 4Humanitas Research Hospital, IBD Unit – Gastroenterology, Milano, Italy, 5São Paulo State University, Digestive Surgery Department, Botucatu, Brazil, 6Gastrosaude, Colorectal Surgery, Marilia, Brazil, 7Heliopolis Hospital, IBD unit, São Paulo, Brazil, 8Cajuru University Hospital – Catholic University of Parana, Gastroenterology, Curitiba, Brazil, 9Humanitas Research Hospital, Medical Biotechnologies and Translational Medicine, Milano, Italy, 10Catholic University of Paraná, Statistics, Curitiba, Brazil, 11Humanitas Research Hospital, IBD Surgery Unit, Milano, Italy

P519. Efficacy of Adalimumab in children and adolescents with moderate/ severe ulcerative colitis
Authors:

E. Volonaki1, M. Martins1, L. Cococcioni1, M. Malamisura1, N. Shah1, K. Lindley1, F. Kiparissi1, M. Elawad1, 1Great Ormond Street Hospital, Paediatric Gastroenterology, London, United Kingdom

P519

Thiopurines Undertreatment among Inflammatory Bowel Disease Patients Referred for antiTNF Therapy

Authors:

V. Sucha*1, 2, B. Kadleckova3, B. Repakova3, L. Jurgos1, S. Kinova2, Z. Zelinkova3

1Outpatient Department of Gastroenterology, Jurgos s.r.o, Bratislava, Slovakia, 2Faculty of Medicine, Comenius University, 1st Department of Internal Medicine, Bratislava, Slovakia, 3IBD Center, Thalion, Bratislava, Slovakia

P520.

Demographic features and long-term follow up outcome comparisons between patients with solo inflammatory bowel disease vs. inflammatory bowel disease and concomitant ankylosing spondylitis

Authors:

Y. Erzin1, H. Eyvazov2, I. Hatemi1, G. Hatemi3, A.F. Celik1, 1Istanbul University Cerrahpasa Medical Faculty, Gastroenterology, Istanbul, Turkey, 2Istanbul University Cerrahpasa Medical Faculty, Internal Medicine, Istanbul, Turkey, 3Istanbul University Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey

P520. Efficacy and safety of leucocytapheresis for active inflammatory bowel disease during pregnancy: therapeutic outcomes in four pregnant cases
Authors:

H. Kinoshita1, R. Kunisaki1, S. Tomohiko1, H. Kimura1, S. Maeda2, 1Yokohama City University Medical Center, Inflammatory Bowel Disease Center, Yokohama, Japan, 2Yokohama City University, Department of Gastroenterology, Yokohama, Japan

P520

Accuracy of rapid fecal calprotectin test in monitoring Inflammatory Bowel Diseases under treatment with TNF-alpha antagonists

Authors:

A. Tursi*1, W. Elisei2, M. Picchio3, A. Penna4, G. Giorgetti5, G. Brandimarte6

1Azienda Sanitaria Locale BAT, Servizio di Gastroenterologia Territoriale, Andria, Italy, 2ASL RMH, Division of Gastroenterology,, Albano Laziale (Rome), Italy, 3“P. Colombo” Hospital, ASL RMH, Division of Surgery, Velletri (Rome), Italy, 4“S. Paolo” Hospital, Division of Gastroenterology, Bari, Italy, 5“S. Eugenio” Hospital, Digestive Endoscopy & Nutrition Unit, Rome, Italy, 6“Cristo Re” Hospital, Division of Internal Medicine and Gastroenterology, Rome, Italy